Business Wire

Pricefx Reimagines Pricing Software with Groundbreaking Product Enhancements

2.12.2020 17:30:00 EET | Business Wire | Press release

Share

Pricefx, the global leader in cloud-native pricing software, today announced the new face of its pricing platform. Unity UI is a sleek, dynamic new look for all of Pricefx’s industry-leading pricing modules. The company has also launched PriceOptimizer AI, a next-generation price optimization solution powered by transparent and predictive machine learning and multi-agent AI. Finally, Pricefx introduced new Accelerators, pre-defined solution building blocks that quickly and easily incorporate best practice functionality. With these new enhancements, Pricefx is now more streamlined, powerful and agile than ever before. Now, businesses using Pricefx can get more done and price more effectively with fewer clicks.

“2020 revealed the critical importance of pricing in a digital-first world and Pricefx invested heavily in developing and refining our pricing platform to ensure that businesses around the world can successfully use our software to build a path to growth,” said Marcin Cichon, CEO and co-founder at Pricefx. “From the new, modern user interface to the groundbreaking AI-powered price optimizer and the pre-built Accelerators, Pricefx is delivering impressive product functionality to the market. We continue to live our commitment to providing customers fast, flexible and friendly solutions that help them achieve revenue and profit goals faster than ever.”

Unity UI

Pricefx platform modules are now unified in a modern, sleek UI that streamlines the user experience by ensuring that everything is at the user’s fingertips. Pricing workflows are simplified with a single application that works across multiple platforms and devices. To reduce management overhead, Pricefx can be customized for different users and easily incorporated into third-party CRM or ERP applications.

PriceOptimizer AI

With PriceOptimizer AI, Pricefx is introducing the industry’s first price optimization engine powered by multi-agent AI, a powerful approach that uses multiple interacting intelligent agents to arrive at the best outcome. With this breakthrough, PriceOptimizer AI can simulate multiple business objectives at once and simultaneously optimize the entire price waterfall at every level of granularity, from list prices to rebates. This means Pricefx customers can align competing business rules, priorities and constraints, such as price increases, competition or margin targets, resulting in far more realistic pricing strategy.

Additionally, users can evaluate multiple best outcomes even when the model is over constrained. They can model price elasticity to see precisely which constraints are impacting the optimized list price, discount or rebate. Then, users can easily change models, simulate the impact of changes and adjust constraints during run-time. This faster, more flexible approach to price optimization achieves massive time savings, with updates to thousands of prices and sales conditions in just minutes.

In combination with “clear box” segmentation and predictive ML algorithms, PriceOptimizer AI delivers transparent and intuitive price optimization, enabling pricing leaders to confidentially arm sales with deal guidance they can stand behind.

“Although the term ‘artificial intelligence’ can conjure up an image of robots taking over the world, the best use of AI is eliminating robotic work from a process so that people are free to use their experience and judgment to make better decisions more consistently,” observed Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Making decisions about optimal pricing within a set of prioritized objectives, business rules and constraints is an ideal use case for AI provided that the system is fully transparent so individuals can trust the outcome. Increasingly, companies are finding that intelligent pricing enables them to improve both revenues and margins with a sustainable competitive advantage.”

Accelerators

With Pricefx Accelerators, customers can use pre-defined solution building blocks to deploy new modules and functionality even faster, while reducing overall effort and cost. By adding industry best practice functionality, Pricefx customers and partners can quickly and easily configure solutions out of the box, while still retaining customization capabilities. Not only do Accelerators reduce implementation effort and time to value, they also lower the total cost of ownership for the Pricefx platform by making it easier to support and enhance functionality.

Specifically, the new Sales Insights Accelerator delivers rapid insights into profitability, margin leakage and profit outliers. Customers can see how margin and revenue change over time based on factors like customer acquisition and variances in price, as well as quickly find and address outliers by analyzing your best and worst performing customers and products.

Availability

Unity UI, PriceOptimizer AI and Accelerators are generally available now as part of the Vesper release.

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Cathy Summers
Summers PR
cathy@summers-pr.com
+1 (415) 483-0480

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release

Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye